The multidisciplinary and interprofessional approach to the management of head and neck cancers
22 - 23 November 2016 - Milan, Italy
The multidisciplinary and interprofessional approach to the management of head and neck cancers

Overview
The “Train-the-Trainer” course is a two-day training workshop designed to promote the interprofessional management of head and neck cancers. Participants will have the chance to increase their understanding of the multidisciplinary cancer care model, acquiring competencies and discussing implementation strategies for their own institutions. Healthcare professionals who have attended the training are then encouraged to disseminate what they have learned and to replicate the multidisciplinary cancer care model in their own country. The programme is designed for a specialized audience composed by the three core members of the multidisciplinary team drawn from the same centre (head and neck surgeon, radiotherapist and medical oncologist).

Learning objectives
By attending this training course, participants will be able to:

- Acquire the competence to train multidisciplinary team (MDT) members in the management of head and neck cancer patients
- Apply new communication modalities to integrate different specialists into the MDT
- Implement plans for leading and sustaining meaningful education and collaborative practice at their own institution, including the legal, regulatory, cost-effectiveness implications as well as the patients’ perspective
- Establish a network among different centers with an effective MDT

Target audience
This course is designed for senior surgeons, radiation oncologists and medical oncologists involved in management of patients with head and neck cancers. In order to make the training effective, it’s recommended that the decision-making members from the same institution (surgeon, radiation-oncologist, medical oncologist) attend the meeting together.
CME Provider

EXCEMED is a non profit foundation dedicated, since the last four decades, to the development of high-quality medical education programmes all over the world.

EXCEMED adheres to the guidelines and standards of the European Accreditation Council for Continuing Medical Education (EACCME®) which states that continuing medical education must be balanced, independent, objective, and scientifically rigorous.

Continuing medical education

EXCEMED (www.excemed.org) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide the following CME activity for medical specialists. The EACCME® is an institution of the European Union of Medical Specialists (UEMS), www.uems.net

The CME course “The multidisciplinary and interprofessional approach to the management of head and neck cancers” held on 22-23 November 2016 in Milan, Italy, is designated for a maximum of 11 (eleven) hours of European CME credits (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EXCEMED adheres to the principles of the Good CME Practice group (gCMEp).
This live educational course takes place at the:

**Palazzo Giureconsulti**  
**Suite 2** (First floor)  
Piazza dei Mercanti, 2  
20123 Milan, Italy

**Language**  
The official language of this live educational course is English.

**CME Provider**  
EXCEMED - Excellence in Medical Education  
Senior Programme Manager: Alessia Addessi  
T +39 06 420413 591 - F +39 06 420413 677  
alessia.addessi@excedmed.org  
Medical Advisor: Cristina Raimondi  
cristina.raimondi@libero.it

**For any logistic support please contact:**  
Meridiano Congress International  
Project Coordinator: Barbara Centini  
T +39 06 88 595 207 - F +39 06 88595 234  
barbara.centini@meridiano.it
Faculty

Antonio Aglione
European Cancer Patient Coalition (ECPC)
Associazione Italiana Laringectomizzati (AILAR)
Milan, Italy

Andreas Dietz
University Department of
Otolaryngology and Plastic Surgery
Leipzig, Germany

Kevin Harrington
Division of Radiotherapy and Imaging
The Institute of Cancer Research
London, UK

Lisa Licitra
Head and Neck Cancer Medical Oncology Unit
Fondazione IRCCS
Istituto Nazionale dei Tumori
Milan, Italy

Sat Parmar
Maxillofacial Department
Queen Elizabeth Hospital and
University Hospitals Birmingham
NHS Foundation Trust
Birmingham, UK

Graeme Poston
Department of Hepatobiliary Surgery
North Western Hepatobiliary Centre
Aintree University Hospitals Foundation Trust
Liverpool, UK

Daniel Schmid
Infinity Unconventional Education
Rome, Italy

Rosanna Tarricone
Department of Policy Analysis and Public Management
CeRGAS Bocconi University
Milan, Italy
Programme
Tuesday, 22 November 2016

9.00 Opening and introduction
L. Licitra (Italy)

Teaching session I Understanding of multidisciplinary cancer care concepts

9.15 Understanding multidisciplinary approach in guidelines for the treatment of head and neck cancer

L1: Oropharyngeal cancer
L. Licitra (Italy)

L2: Laryngeal and hypopharyngeal cancers
K. Harrington (UK)

L3: Oral cavity cancer
A. Dietz (Germany)

10.45 Coffee break

11.15 L4: Rationale, definitions and benefits of working in a multidisciplinary team
L. Licitra (Italy)

11.30 L5: The multidisciplinary cancer care model at the Istituto Nazionale Tumori
L. Licitra (Italy)

11.45 L6: The multidisciplinary cancer care model at the Royal Marsden Hospital
K. Harrington (UK)

12.00 L7: The multidisciplinary cancer care model at the University Hospital Leipzig
A. Dietz (Germany)

12.15 Summary and discussion
L. Licitra (Italy)

12.45 Lunch

Legend: L: Lecture  : Interactive session  : Round table
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.45</td>
<td>L8: Core competencies for working in a multidisciplinary team</td>
</tr>
<tr>
<td></td>
<td>L. Licitra (Italy)</td>
</tr>
<tr>
<td>14.30</td>
<td>L9: Effective communication among specialists</td>
</tr>
<tr>
<td></td>
<td>D. Schmid (Italy)</td>
</tr>
<tr>
<td>15.15</td>
<td>Communication among specialists in practice: clinical case discussion I</td>
</tr>
<tr>
<td>15.45</td>
<td>Summary and take home messages</td>
</tr>
<tr>
<td>16.30</td>
<td>End of the first day</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>9.00</td>
<td>L10:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>9.30</td>
<td></td>
</tr>
<tr>
<td>10.30</td>
<td>L11:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00</td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td>L12:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td>L13:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
</tr>
<tr>
<td>13.30</td>
<td>L14</td>
</tr>
<tr>
<td>14.00</td>
<td></td>
</tr>
<tr>
<td>14.30</td>
<td></td>
</tr>
<tr>
<td>15.00</td>
<td>L15</td>
</tr>
<tr>
<td>15.30</td>
<td></td>
</tr>
</tbody>
</table>
EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of EXCEMED. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

**Antonio Aglione**
Declared no potential conflict of interest.

**Andreas Dietz**
Declared receipt of grants and contracts from Merck. He declared to be member of a company advisory board, board of directors or other similar groups and in company sponsored speakers’ bureau: MSD, Merck.

**Kevin Harrington**
Declared receipt of grants and contracts from: Biotech, Genetech. He declared receipt of honoraria or consultation fees from: Amgen, BMS, Merck, Astrazeneca, Pfizer. He declared to be member of a company advisory board, board of directors or other similar groups: Merck, BMS. He declared participation in a company sponsored speakers’ bureau: Merck, Amgen.

**Lisa Licitra**
Declared receipt of consultation fees from: EISAI, BMS, Glaxo, Merck, Amgen, Boehringer Ingelheim, Debiopharm, VentiRx, Sobi, Roche, Celgene.

**Graeme Poston**
Declared no potential conflict of interest.

**Rosanna Tarricone**
Declared no potential conflict of interest.

The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of 11 November 2016.

**Sat Parmar**
All EXCEMED programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of EXCEMED. This independent programme is made possible thanks to an educational grant received from Merck KGaA, Darmstadt, Germany.
Improving the patient’s life through medical education

www.excemed.org